Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR
SKBBYDrugs in Pipeline
56
Phase 3 Programs
21
Upcoming Catalysts
20
Next Catalyst
This month
Market Overview
Stock performance and key metrics
20 upcoming, 1 past
PRT-064040 nasal spray Phase 2 Est. Readout
Primary completion for PRT-064040 nasal spray trial (NCT07304518) in Migraine
Source19 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
BL-M07D1
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
A166
HER2-positive Breast Cancer
Eribulin
HR+HER2- Breast Cancer
SI-B001
Non-small Cell Lung Adenocarcinoma
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Non-small Cell Lung Cancer
KL-A167
Nasopharyngeal Carcinoma
Double blind control period A140
Metastatic Colorectal Cancer
BL-B01D1
Advanced Biliary Tract Cancer
KN035 plus Gemcitabine & oxaliplatin
Biliary Tract Neoplasms
Investigator's choice of chemotherapy
Gastric Adenocarcinoma
Pemetrexed+Cisplatin or Carboplatin
Non-small Cell Lung Cancer
HSK3486
Sedation or Anesthesia
BL-M05D1
Gastric Cancer
carboplatin or cisplatin
Non-Small Cell Lung Cancer
Pertuzumab
HER2-positive Breast Cancer
SKB264
Metastatic Breast Cancer
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
HER2-low Breast Cancer
T-DM1
HER2-positive Breast Cancer
Docetaxel or Paclitaxel
Urothelial Carcinoma
Wujia Yizhi granules
Alzheimer's Dementia
Propofol
Colonoscopy
BL-B01D1 for Injection
Recurrent Glioblastoma
Lenvatinib + Envafolimab
Solid Tumors
SKB518 for injection
Advanced Gynecological Malignancies
BL-M02D1
Non-small Cell Lung Cancer
PD-1 monoclonal antibody
Extensive-stage Small-cell Lung Cancer
Axitinib
Renal Cancer
PRT-064040 nasal spray
Migraine
SKB103 for injection monotherapy
Advanced Solid Tumors
Tagitanlimab
Prostate Cancer (Adenocarcinoma)
SKB500
Esophageal Squamous Cell Carcinoma
Furmonertinib
Non-Small Cell Lung Cancer
SKB565
Advanced Solid Tumors
SKB571
HNSCC
Low Dose PRT042 nasal spray
Major Depressive Disorder (MDD
SKB118 Injection
Advanced Solid Tumors
SKB264+SKB118
NSCLC
SKB105 for injection Monotherapy
Advanced Solid Tumors
KN035
Solid Tumor
SI-B003
Esophageal Cancer
SKB571 for injection
Lung Cancer (Non-Small Cell)
Test product HY0001a for injection
Solid Tumor
GNC-035
Non-hodgkin's Lymphoma
Envafolimab+Lenvatinib
Advanced Endometrial Cancer
AP or TP
Non Small Cell Lung Cancer
SKB500 Powder for Injection
Small Cell Lung Cancer
Lenvatinib
Advanced Hepatocellular Carcinoma
GNC-038
Diffuse Large B-cell Lymphoma
SKB518
Lung Carcinoma
KL-A167 Injection
Nasopharyngeal Carcinoma
KL590586 Capsule
Advanced Solid Tumor
PD-1
Urothelial Carcinoma
Clarithromycin
Ovarian Epithelial Cancer
Test product: HYP-2090PTSA
Safety
HY05350 for injection
Advanced Solid Tumor
Envafolimab
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BL-M07D1 | Phase 3 | Her2-positive/Low-expression Urinary and Digestive Tract Tumors | - | - |
A166 | Phase 3 | HER2-positive Breast Cancer | - | - |
Eribulin | Phase 3 | HR+HER2- Breast Cancer | - | - |
SI-B001 | Phase 3 | Non-small Cell Lung Adenocarcinoma | - | - |
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection | Phase 3 | Non-small Cell Lung Cancer | - | - |
KL-A167 | Phase 3 | Nasopharyngeal Carcinoma | - | - |
Double blind control period A140 | Phase 3 | Metastatic Colorectal Cancer | - | - |
BL-B01D1 | Phase 3 | Advanced Biliary Tract Cancer | - | - |
KN035 plus Gemcitabine & oxaliplatin | Phase 3 | Biliary Tract Neoplasms | - | - |
Investigator's choice of chemotherapy | Phase 3 | Gastric Adenocarcinoma | - | - |
Pemetrexed+Cisplatin or Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
HSK3486 | Phase 3 | Sedation or Anesthesia | - | - |
BL-M05D1 | Phase 3 | Gastric Cancer | - | - |
carboplatin or cisplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Pertuzumab | Phase 3 | HER2-positive Breast Cancer | - | - |
SKB264 | Phase 3 | Metastatic Breast Cancer | - | - |
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel | Phase 3 | HER2-low Breast Cancer | - | - |
T-DM1 | Phase 3 | HER2-positive Breast Cancer | - | - |
Docetaxel or Paclitaxel | Phase 3 | Urothelial Carcinoma | - | - |
Wujia Yizhi granules | Phase 3 | Alzheimer's Dementia | - | - |
Propofol | Phase 3 | Colonoscopy | - | - |
BL-B01D1 for Injection | Phase 2 | Recurrent Glioblastoma | - | - |
Lenvatinib + Envafolimab | Phase 2 | Solid Tumors | - | - |
SKB518 for injection | Phase 2 | Advanced Gynecological Malignancies | - | - |
BL-M02D1 | Phase 2 | Non-small Cell Lung Cancer | - | - |
PD-1 monoclonal antibody | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
Axitinib | Phase 2 | Renal Cancer | - | - |
PRT-064040 nasal spray | Phase 2 | Migraine | - | - |
SKB103 for injection monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
Tagitanlimab | Phase 2 | Prostate Cancer (Adenocarcinoma) | - | - |
SKB500 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
Furmonertinib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
SKB565 | Phase 2 | Advanced Solid Tumors | - | - |
SKB571 | Phase 2 | HNSCC | - | - |
Low Dose PRT042 nasal spray | Phase 2 | Major Depressive Disorder (MDD | - | - |
SKB118 Injection | Phase 2 | Advanced Solid Tumors | - | - |
SKB264+SKB118 | Phase 2 | NSCLC | - | - |
SKB105 for injection Monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
KN035 | Phase 2 | Solid Tumor | - | - |
SI-B003 | Phase 2 | Esophageal Cancer | - | - |
SKB571 for injection | Phase 2 | Lung Cancer (Non-Small Cell) | - | - |
Test product HY0001a for injection | Phase 2 | Solid Tumor | - | - |
GNC-035 | Phase 2 | Non-hodgkin's Lymphoma | - | - |
Envafolimab+Lenvatinib | Phase 2 | Advanced Endometrial Cancer | - | - |
AP or TP | Phase 2 | Non Small Cell Lung Cancer | - | - |
SKB500 Powder for Injection | Phase 2 | Small Cell Lung Cancer | - | - |
Lenvatinib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
GNC-038 | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
SKB518 | Phase 2 | Lung Carcinoma | - | - |
KL-A167 Injection | Phase 2 | Nasopharyngeal Carcinoma | - | - |
KL590586 Capsule | Phase 2 | Advanced Solid Tumor | - | - |
PD-1 | Phase 2 | Urothelial Carcinoma | - | - |
Clarithromycin | Phase 2 | Ovarian Epithelial Cancer | - | - |
Test product: HYP-2090PTSA | Phase 2 | Safety | - | - |
HY05350 for injection | Phase 2 | Advanced Solid Tumor | - | - |
Envafolimab | Phase 2 | Solid Tumor | - | - |
first-line treatment for advanced triple-negative breast cancer (TNBC)
1 drug in this indication
Recurrent or metastatic esophageal squamous cell carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 56 drug candidates in Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's (SKBBY) pipeline across Phase 3, Phase 2. Its lead program is BL-M07D1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's next FDA catalyst?→
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's (SKBBY) next tracked catalyst is a Phase 3 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SKBBY biotech catalysts?→
Add SKBBY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.